OncoPlus

1200 Gene NGS Panel

The OncoPlus panel is a targeted next generation sequencing (NGS) assay that has the capability to cover 1,213 cancer-related genes for personalized assessments of both solid tumors and hematological malignancies. Variant calling in 147 genes are reportable for clinical patient care.

In the past 5 years, University of Chicago has been developing the cancer genomics program with the goal of providing cancer patients with the best possible care in the world at an affordable price. The design of OncoPlus panel was developed in consultation with leading oncologists where panel not only includes the actionable targets today but also potential future targets.

In addition to mutations and ALK/RET/ROS1 gene fusions, the expanded content allows for detection of microsatellite instability, copy number variations, and tumor mutational burden.

Microsatellite instability detection involves analysis of a collection of 338 microsatellite loci, allowing pan-tumor detection of MSI in all cases, even those with low suspicion for MSI which have not been tested via immunohistochemistry. The addition of copy number variations provides a range of actionable data, including evaluation of losses in common tumor suppressor genes and amplifications of genes such as ERBB2 (HER2), MET, and CCND1/2/3 for which inhibitors are available.

Large-scale sequencing allows for robust quantification of tumor mutational burden (TMB), an emerging biomarker with potential utility in immunotherapy selection. For cases with high TMB scores, we can also evaluate the mutational signature of the tumor for clues to its etiology. For example, the UV exposure signature can be used to establish a cutaneous origin of certain cases of metastatic squamous cell carcinoma.

In addition, we provide information on check point inhibitors (PD1 and PD1-L) by immunohistochemistry.

OncoPlus 1200 Gene NGS Panel is the most commonly used test at UChicago for molecular profiling of patients, as it permits detection of the widest range of actionable findings.

Vinay Kumar, MD MBBS, Editor Robbins Pathology, discusses Genomic Pathology

Alice Hogge and Arthur A. Baer Distinguished Service Professor of Pathology, Biologic Sciences Division and the Pritzker Medical School, University of Chicago



"We feel that all patients should benefit from the existing and potential therapeutic targets, regardless of the geographic location."
Dr Vinay Kumar